2004
DOI: 10.1159/000077994
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Objective: To evaluate efficacy and toxicity of the combination of irinotecan and gemcitabine in pretreated patients having small-cell lung cancer. Patients andMethods: Thirty-one patients (median age 60 years, performance status 0–1 in 87% and 2 in 13% of the patients) with limited or extensive-stage disease, refractory or relapsing after at least one prior chemotherapy regimen, received gemcitabine 1,000 mg/m2 on days 1 and 8 and irinotecan 300 mg/m2 on day 8, every 21 days. Sixteen (52… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
7
1

Year Published

2006
2006
2017
2017

Publication Types

Select...
6
2

Relationship

1
7

Authors

Journals

citations
Cited by 15 publications
(8 citation statements)
references
References 17 publications
(17 reference statements)
0
7
1
Order By: Relevance
“…In a previous phase II study conducted by our group [15] the IG regimen was administered, to 31 SCLC patients (48% of them had refractory disease) resulting in an ORR of 10%, a TTP of 4.5 months and a median OS of 6 months; the lower ORR reported compared to the current study, could be attributed to the fact, that more than 50% of patients, received the IG regimen as third or more line of therapy. Two studies [16,17] used a relatively different regimen in 35 sensitive and 71 refractory SCLC patients (gemcitabine 1000 mg/m 2 , days 1 and 8, irinotecan 100 mg/m 2 , days 1 and 8; every 21 days) and reported a similar response rate of 17% and 21%, respectively.…”
Section: Discussioncontrasting
confidence: 54%
See 2 more Smart Citations
“…In a previous phase II study conducted by our group [15] the IG regimen was administered, to 31 SCLC patients (48% of them had refractory disease) resulting in an ORR of 10%, a TTP of 4.5 months and a median OS of 6 months; the lower ORR reported compared to the current study, could be attributed to the fact, that more than 50% of patients, received the IG regimen as third or more line of therapy. Two studies [16,17] used a relatively different regimen in 35 sensitive and 71 refractory SCLC patients (gemcitabine 1000 mg/m 2 , days 1 and 8, irinotecan 100 mg/m 2 , days 1 and 8; every 21 days) and reported a similar response rate of 17% and 21%, respectively.…”
Section: Discussioncontrasting
confidence: 54%
“…infusion, on days 1 and 8; irinotecan was administered on day 8 as a 90-min i.v. infusion, at a dose of 300 mg/m 2 [15]. For the monotherapy arm (I), treatment consisted of irinotecan administered i.v.…”
Section: Treatmentmentioning
confidence: 99%
See 1 more Smart Citation
“… 124 Doublets of gemcitabine and other agents, for example, irinotecan, vinorelbine and cocetaxel yield poor response rates of no more than 17% in pre-treated patients. 125 130 In the first-line setting in poor performance elderly patients with ED, gemcitabine and docetaxel resulted in an unimpressive RR of 23% and median survival of four months. 131 …”
Section: Newer Agentsmentioning
confidence: 99%
“…As doublets, these include cisplatin [39], weekly or every three weeks carboplatin [40,41], etoposide [42], gemcitabine [43,44], ifosfamide [45] and paclitaxel [46]. The responses vary from 10 to 94%, and the MST ranges from 5.8 to 8.9 months.…”
Section: Irinotecan-containing Regimens For Relapsed or Refractory Sclcmentioning
confidence: 99%